We are live on ! Find out more
PBYI icon

Puma Biotechnology

132 hedge funds and large institutions have $183M invested in Puma Biotechnology in 2025 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 43 increasing their positions, 36 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

172,500% more call options, than puts

Call options by funds: $1.73M | Put options by funds: $1K

92% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 12

62% more capital invested

Capital invested by funds: $113M → $183M (+$70M)

19% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 36

9% more funds holding

Funds holding: 121132 (+11)

2.14% more ownership

Funds ownership: 66.11%68.26% (+2.1%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
132
Holders Change
+11
Holders Change %
+9.09%
% of All Funds
1.73%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
23
Increased
43
Reduced
36
Closed
12
Calls
$1.73M
Puts
$1K
Net Calls
+$1.73M
Net Calls Change
+$1.4M
Name Holding Trade Value Shares
Change
Change in
Stake
Assenagon Asset Management
51
Assenagon Asset Management
Luxembourg
$388K +$309K +72,979 New
Invesco
52
Invesco
Georgia
$339K +$58.7K +13,835 +28%
Lazard Asset Management
53
Lazard Asset Management
New York
$335K +$268K +63,147 New
RRA
54
Round Rock Advisors
Connecticut
$330K +$277K +65,396 New
WG
55
Winton Group
United Kingdom
$326K +$260K +61,324 New
Macquarie Group
56
Macquarie Group
Australia
$325K
RhumbLine Advisers
57
RhumbLine Advisers
Massachusetts
$319K -$2.59K -610 -1%
Two Sigma Investments
58
Two Sigma Investments
New York
$298K -$570K -134,495 -71%
MGP
59
Metis Global Partners
California
$296K
State of Wisconsin Investment Board
60
State of Wisconsin Investment Board
Wisconsin
$288K +$230K +54,318 New
GCM
61
Graham Capital Management
Connecticut
$280K +$224K +52,708 New
LPL Financial
62
LPL Financial
California
$272K -$8.44K -1,990 -4%
Cambridge Investment Research Advisors
63
Cambridge Investment Research Advisors
Iowa
$270K +$216K +50,823 New
VEA
64
Virtus ETF Advisers
New York
$250K -$35K -8,259 -15%
Bank of America
65
Bank of America
North Carolina
$239K -$94.5K -22,275 -33%
PCM
66
Prelude Capital Management
New York
$204K +$21.2K +5,000 +15%
Wells Fargo
67
Wells Fargo
California
$173K +$19.1K +4,505 +16%
DOA
68
D'Orazio & Associates
Virginia
$170K +$71.7K +16,906 +113%
Deutsche Bank
69
Deutsche Bank
Germany
$163K
SPA
70
Sherbrooke Park Advisers
New York
$162K +$129K +30,527 New
HT
71
Headlands Technologies
Illinois
$155K +$117K +27,636 +1,797%
KCM
72
Kathmere Capital Management
Pennsylvania
$148K +$32.9K +7,749 +38%
XT
73
XTX Topco
Cayman Islands
$136K -$335K -78,900 -76%
SA
74
Sanctuary Advisors
Indiana
$127K +$101K +23,866 New
CWM
75
C2C Wealth Management
Arizona
$122K +$10.2K +2,400 +12%

PBYI Hedge Fund Activity: Q3 2025 in Review

132 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q3 2025, worth a combined $183M — up 62% from $113M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new PBYI positions and 12 closed out — a net gain of 11 holders — while 43 added to existing stakes and 36 trimmed.

The largest buyer was Russell Investments Group, adding an estimated $4.09M. The largest seller was Janus Henderson Group, exiting entirely with an estimated $2.56M sold.

  • 132 institutional investors held Puma Biotechnology (PBYI) as of Q3 2025, up from 121 in Q2 2025.
  • Funds reported $183M of Puma Biotechnology stock for Q3 2025, up 62% quarter-over-quarter.
  • 23 funds opened new Puma Biotechnology positions in Q3 2025 and 12 closed out, a net change of +11 holders.
  • The largest Puma Biotechnology buyer in Q3 2025 was Russell Investments Group, an estimated $4.09M added.
  • The largest Puma Biotechnology seller in Q3 2025 was Janus Henderson Group, an estimated $2.56M sold.

Based on aggregated 13F filings for Q3 2025.